6061
In the course of their reports the lawyers informed the pharma business representatives on main issues in the agreements that may lead to the AMCU’s claims, on the prerequisites of such “hidden pitfalls”, and on the ways to mitigate the corresponding risks.
5862
The document highlights the issues of pharma markets operation, the reasons for unworkable competition emergence on these markets, proposes the remedies for the basis of competition law violations by market players and regulators.
8303
The Antimonopoly Committee of Ukraine imposed a penalty on pharmaceutical company «Servier Ukraine» LLC and Ukrainian distributors for anticompetitive concerted actions during 2011-2012.
7788
Another national ranking of legal industry noted Legal Alliance among the leading companies serving pharma.
6793
AMCU’s position was based on the fact that the distributers were selling medicinal products through the state procurement procedures for the prices higher than the sale prices for the pharmacies, by using different approaches to price formation.
6224
Parties are now also expected to provide more thorough reasoning, based on an economic analysis of transactions and their consequences, in order to obtain a permit for conducting transactions.
5889
The AMCU adopted new guidelines for the protection of economic competition.
15664
Legal Alliance Company represented the interests of GlaxoSmithKline Ukraine at the Antimonopoly Committee of Ukraine in relation to conclusions obtainment in th
5746
Recommendations for penalties calculation charged for the violation of the legislation on economic competition protection.
5180
On January, 12 the Cabinet of Ministers Resolution «On Efforts in Stabilization of Prices for Medicinal Products and Medical Devises».
